The FLOW trial results are live at @nejm as well

#ERA24



Primary composite kidney ✅
CV Death✅
All cause death ✅
GFR slope ✅
First MACE ✅
Kidney specific composite ✅ nejm.org/doi/full/10.10…
Pretty consistent in all subgroups

FLOW at #ERA24

First up is @SanthiKGanesh on FMD molecular and genetic mechanisms
This is a *systemic* arteriolopathy not just renal
#hypertension23

Broad classifications - from
And how the presentations vary
@FMDartery @FMDChat
#Hypertension23 ahajournals.org/doi/10.1161/01…

JC @VelezNephHepato blows up the IAC criteria for defining #Hepatorenal syndrome

Really impractical and not useful
#ApExPathshala Interestingly enough, norepinephrine is possibly very similar to Terlipressin in hepatorenal syndrome as long as the MAP goes up (which is key!) @VelezNephHepato at
#ApExPathshala

Tony @tony_breu holding court on renal physiology in ATN at #ApExPathshala
Is TGF in ischemic ATN good or bad? The seminal paper of course is Klaus Thurau on Acute Renal Success
#ApExPathshala pubmed.ncbi.nlm.nih.gov/961698/

The #Tweetorial guru @tony_breu up next with a fresh tweetorial presentation (he will post it tomorrow for the rest of you)

#ApExPathshala Tony @tony_breu walking us through his research that underlies a single tweetorial

It’s intense.

Why? is a tough question.

#ApExPathshala

Published! (Months after being FDA approved) by @IgAN_JBarratt et al

The phase 3A part of targeted release budesonide (called Nefecon) in IgA

kidney-international.org/article/S0085-…

They included IgA with proteinuria > 1g and GFR 35 to 90 + max supported RASi

see how that worked out:

1/ Safety on all presented (note more AEs in Nefecon group)

Efficacy on those with 9 month follow up

2/